Literature DB >> 718158

Safety of oral vancomycin in functionally anephric patients.

C S Bryan, W L White.   

Abstract

Administration of a vancomycin oral solution, 2 g daily for 16 days, to functionally anephric patients without inflammatory bowel disease resulted in assayable but low (</=0.66 mug/ml) serum levels in two of the five volunteers.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 718158      PMCID: PMC352521          DOI: 10.1128/AAC.14.4.634

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  7 in total

1.  Some laboratory and clinical experiences with a new antibiotic, vancomycin.

Authors:  J E GERACI; F R HEILMAN; D R NICHOLS; G T ROSS; W E WELLMAN
Journal:  Proc Staff Meet Mayo Clin       Date:  1956-10-17

2.  Clindamycin-associated colitis in hamsters: protection with vancomycin.

Authors:  J G Bartlett; A B Onderdonk; R L Cisneros
Journal:  Gastroenterology       Date:  1977-10       Impact factor: 22.682

3.  The protective effect of vancomycin on clindamycin-induced colitis in hamsters.

Authors:  R A Browne; R Fekety; J Silva; D I Boyd; C O Work; G D Abrams
Journal:  Johns Hopkins Med J       Date:  1977-10

4.  Sensitive bioassay for vancomycin.

Authors:  C A Walker; B Kopp
Journal:  Antimicrob Agents Chemother       Date:  1978-01       Impact factor: 5.191

5.  Simplified, accurate method for antibiotic assay of clinical specimens.

Authors:  J V Bennett; J L Brodie; E J Benner; W M Kirby
Journal:  Appl Microbiol       Date:  1966-03

6.  Infection in acute leukemia patients receiving oral nonabsorable antibiotics.

Authors:  D M Hahn; S C Schimpff; C L Fortner; A C Smyth; V M Young; P H Wiernik
Journal:  Antimicrob Agents Chemother       Date:  1978-06       Impact factor: 5.191

Review 7.  Vancomycin revisited.

Authors:  F V Cook; W E Farrar
Journal:  Ann Intern Med       Date:  1978-06       Impact factor: 25.391

  7 in total
  5 in total

1.  Clearance from dialysate and equilibration of intraperitoneal vancomycin in continuous ambulatory peritoneal dialysis.

Authors:  D Neal; G R Bailie
Journal:  Clin Pharmacokinet       Date:  1990-06       Impact factor: 6.447

Review 2.  Does oral vancomycin use necessitate therapeutic drug monitoring?

Authors:  Nevio Cimolai
Journal:  Infection       Date:  2019-11-11       Impact factor: 3.553

3.  Design of vancomycin RS-100 nanoparticles in order to increase the intestinal permeability.

Authors:  Badir Delf Loveymi; Mitra Jelvehgari; Parvin Zakeri-Milani; Hadi Valizadeh
Journal:  Adv Pharm Bull       Date:  2012-02-15

Review 4.  Accidental and iatrogenic causes of acute kidney injury.

Authors:  Katherine Twombley; Michel Baum; Jyothsna Gattineni
Journal:  Curr Opin Pediatr       Date:  2011-04       Impact factor: 2.856

Review 5.  Clinical pharmacokinetics of vancomycin.

Authors:  G R Matzke; G G Zhanel; D R Guay
Journal:  Clin Pharmacokinet       Date:  1986 Jul-Aug       Impact factor: 6.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.